European Commission Approves Cabometyx® in Combination With Opdivo® as a First-Line Treatment for Patients Living With Advanced Renal Cell Carcinoma
Go back to European Commission Approves Cabometyx® in Combination With Opdivo® as a First-Line Treatment for Patients Living With Advanced Renal Cell Carcinoma| SPDR S&P INTERNATIONAL INDUSTRIAL SECTOR (NYSE: IPN) | Delayed: 34.71 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.71 | 52 Week High | $30.88 | |||
| Open | $0.00 | 52 Week Low | $24.64 | |||
| Day High | $34.71 | P/E | N/A | |||
| Day Low | $34.71 | EPS | $0.00 | |||
| Volume | 741,680 | |||||
| Ipsen S.A. Sponsored ADR (AMEX: IPSEY) | Delayed: 30.16 -0.38 (1.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.54 | 52 Week High | $17.79 | |||
| Open | $30.16 | 52 Week Low | $13.01 | |||
| Day High | $30.16 | P/E | N/A | |||
| Day Low | $30.16 | EPS | $0.00 | |||
| Volume | 366 | |||||
